| |
Total Plasma |
Muscle |
Subcutaneous |
| MS |
CPB+DHCA |
MS |
CPB+DHCA |
MS |
CPB+DHCA |
AUC
(μg*min* mL-1) |
5220.1
(4275.5-6487.1) |
21844.1
(16527.4-26587.8) |
3720.3
(3194.0-2121.3) |
5611.4
(4188.1-5465.8) |
3989.5
(3575.0,-4225.8) |
6289.5
(4188.3-8408.2) |
Cmax 1
(μg /mL) |
159.5
(135.1-192.8) |
189.1
(147.9 – 238.8) |
54.8
(44.6-68.2) |
26.3
(23.5-42.6) |
57.7
(56.7-62.4) |
47
(41.8-49.0) |
Tmax 1
(min) |
5
(5-5) |
5
(5-5) |
15
(15,-19) |
30
(30-30) |
30
(26-30) |
30
(30-30) |
Cmax 2
(μg /mL) |
- |
111.4
(98.3-122.5) |
- |
49.3
(41.8-56.8) |
- |
40.7
(36.7-47.8) |
Tmax 2
(min) |
- |
5
(4-11) |
- |
98
(26-141) |
- |
95
(15-176) |
Total Clearance
(L/hr) |
0.7*
(0.6-0.8) |
0.3*
(0.3-0.4) |
- |
- |
- |
- |
| Values displayed as medians (IQR).Cmax2 and Tmax2 are not reported for the MS group as they received only one dose of cefazolin.Total clearance is only able to be calculated from plasma samples so is not reported for the microdialysis samples.Significant p values reported below were calculated using the Wilcoxon rank sum test.Abbreviations: MS = median sternotomy; CPB+DHCA = cardiopulmonary bypass with deep hypothermic circulatory arrest; AUC = Area under the concentration-time curve; Cmax1 = maximum concentration after dose 1; Cmax2 = maximum concentration after dose 2; Tmax1 = time to maximum concentration after dose 1; Tmax2 = time to maximum concentration after dose 2; μg = microgram; mL = milliliter; min = minutes; L = liters; hr = hour.* P = 0.03 |
|
